These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 23325831)

  • 1. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
    Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
    Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
    Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
    Pien GC; Basner-Tschakarjan E; Hui DJ; Mentlik AN; Finn JD; Hasbrouck NC; Zhou S; Murphy SL; Maus MV; Mingozzi F; Orange JS; High KA
    J Clin Invest; 2009 Jun; 119(6):1688-95. PubMed ID: 19436115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
    Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
    Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
    He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
    Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
    Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
    J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
    Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
    Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
    J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes.
    Hui DJ; Basner-Tschakarjan E; Chen Y; Davidson RJ; Buchlis G; Yazicioglu M; Pien GC; Finn JD; Haurigot V; Tai A; Scott DW; Cousens LP; Zhou S; De Groot AS; Mingozzi F
    Mol Ther; 2013 Sep; 21(9):1727-37. PubMed ID: 23857231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
    Lisowski L; Dane AP; Chu K; Zhang Y; Cunningham SC; Wilson EM; Nygaard S; Grompe M; Alexander IE; Kay MA
    Nature; 2014 Feb; 506(7488):382-6. PubMed ID: 24390344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
    Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
    Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
    Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
    Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.
    Li H; Tuyishime S; Wu TL; Giles-Davis W; Zhou D; Xiao W; High KA; Ertl HC
    Mol Ther; 2011 Mar; 19(3):536-46. PubMed ID: 21157435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.
    Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
    Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
    Front Immunol; 2018; 9():844. PubMed ID: 29725339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.